Imaging Prostate Cancer

Jung, Adam J.; Westphalen, Antonio C.

doi:10.1016/j.rcl.2012.08.001

Cited by 17 publications

(15 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Multiparametric magnetic resonance (MR) imaging is an increasingly used modality for prostate tumor detection and staging (11)(12)(13)(14)(15)(16), particularly in candidates for radical prostatectomy (17)(18)(19)(20)(21)(22). However, its performance varies depending on which combination of positive features is selected for cancer diagnosis (23) and the size and aggressiveness of the prostate cancer (24).…”

Section: Implications For Patient Carementioning

confidence: 99%

Prostate Cancer: Diagnostic Performance of Real-time Shear-Wave Elastography

Jm¹,

et al. 2015

View full text Add to dashboard Cite

show abstract

Section: Implications For Patient Carementioning

confidence: 99%

Prostate Cancer: Diagnostic Performance of Real-time Shear-Wave Elastography

Jm¹,

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Diagnostic criteria of prostate cancer in MRI findings were: focal area(s) revealing low signal intensity on T2W images and focal lesion restriction on ADC maps, International Journal of Hematology and Oncology early contrast enhancement with fast washout, and high blood vessel permeability on dynamic contrast-enhanced images. 25,26 Additionally, prostate tumors were seen as hyperintense lesions with high b-values.…”

Section: Discussionmentioning

confidence: 99%

Correlation of Clinical Risk Factors with Diffusion-Weighted Magnetic Resonance Images in Prostate Cancer Patients Treated with Definitive Radiotherapy

Erbay¹

2015

UHOD

View full text Add to dashboard Cite

This study is aimed to correlate apparent diffusion coefficient (ADC) values and clinical T-stage, serum PSA, pathology Gleason scores. We also further analyzed whether ADC values could be used to appropriately define the risk groups. 135 biopsy-proven, radiotherapy-(RT)-treated, prostate cancer patients who underwent pre-RT DW-MRI and standard T2W pelvic MRI were included. ADC and normalized ADC (nADC) values were calculated from DW-MRI delivered a median 8.1 weeks after prostate biopsy. ADC values were correlated with clinical risk factor values by using Pearson correlation test. ADCs in low-, intermediate-, and high-risk patients were 0.873±0.122X10 -3 mm 2 /s, 0.763±0.124X10 -3 mm 2 /s, and 0.701±0.132X10 -3 mm 2 /s (p= 0.001), respectively. Patients with preRT PSA <10 ng/mL had significantly higher ADCs than patients with preRT PSA 10-20 ng/mL (p= 0.02) or >20 ng/mL (p< 0.001). Mean ADC for patients with Gleason score <7 was significantly higher than patients scoring 7 (p= 0.001) or >7 (p < 0.001). Clinical stage 20 ng/mL (p< 0.001) olan hastalara göre istatistiksel olarak anlamı derecede yüksek ADC değerlerine sahipti. Gleason Skoru <7 olan hastalar için ortalama ADC skoru, gleason 7 (p = 0.001) veya >7 (p < 0.001) olanlara göre anlamlı derecede yüksekti. Klinik evre 2b (p < 0.001) hastalara ...

show abstract

“…Prostate carcinoma lymph node staging is limited by poor sensitivity and specificity of anatomical imaging modalities [13,14,15]. Molecular imaging of lymph node metastases by positron emission tomography (PET) is booming nowadays.…”

Section: Introductionmentioning

confidence: 99%

EpCAM Expression in Lymph Node and Bone Metastases of Prostate Carcinoma: A Pilot Study

Campos

Hoving

Rosati

et al. 2016

IJMS

View full text Add to dashboard Cite

There is an urgent need for new imaging modalities in prostate carcinoma staging. A non-invasive modality that can assess lymph node and bone metastases simultaneously is preferred. Epithelial cell adhesion molecule (EpCAM) is a membranous protein of interest as an imaging target since it is overexpressed in prostatic carcinoma compared with benign prostate epithelium and compared with stroma. However, EpCAM expression in lymph node metastases is sparsely available in the literature and EpCAM expression in bone metastases is yet unknown. The current study evaluates the expression of EpCAM in prostate carcinoma lymph nodes, in matched normal lymph nodes, in prostate carcinoma bone metastases, and in normal bone by immunohistochemistry. EpCAM was expressed in 100% of lymph node metastases (21 out of 21), in 0% of normal lymph nodes (0 out of 21), in 95% of bone metastases (19 out of 20), and in 0% of normal bone (0 out of 14). Based on these results, EpCAM may be a feasible imaging target in prostate carcinoma lymph node and bone metastases. Prospective clinical trials are needed to confirm current results. Preoperative visualization of prostate carcinoma metastases will improve disease staging and will prevent unnecessary invasive surgery.

show abstract

Imaging Prostate Cancer

Cited by 17 publications

References 50 publications

Prostate Cancer: Diagnostic Performance of Real-time Shear-Wave Elastography

Prostate Cancer: Diagnostic Performance of Real-time Shear-Wave Elastography

Correlation of Clinical Risk Factors with Diffusion-Weighted Magnetic Resonance Images in Prostate Cancer Patients Treated with Definitive Radiotherapy

EpCAM Expression in Lymph Node and Bone Metastases of Prostate Carcinoma: A Pilot Study

Contact Info

Product

Resources

About